I think that's right -- Missling is not willing to release data with anything left unexplored. And if 2-73 continues to demonstrate wider and wider effects, he is obliged to extend his earlier timelines. We see evidence of changes in trajectory driven by thorough analyses of the data: From individual, unconnected trials, to a common mRNA biomarker and a pivot toward describing blarcamasine as a CNS platform drug (with chromatin-repairing effect), to a plan for a preventative AD trial.
The scope of the strategy, driven by intensive analysis, keeps increasing. This suggests an ongoing, quite successful iterative learning process. That will take, and has taken, more time to complete than one and done trials. Well worth the wait.
Market Data 
Markets 
AI
